M
Michael Sebag
Researcher at McGill University Health Centre
Publications - 86
Citations - 3390
Michael Sebag is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 16, co-authored 61 publications receiving 2842 citations. Previous affiliations of Michael Sebag include National Institutes of Health & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Jonathan J Keats,Rafael Fonseca,Marta Chesi,Roelandt F.J. Schop,Angela Baker,Wee Joo Chng,Scott Van Wier,Rodger E. Tiedemann,Chang Xin Shi,Michael Sebag,Esteban Braggio,Travis J. Henry,Yuan Xiao Zhu,Homer Fogle,Tammy Price-Troska,Gregory J. Ahmann,Catherine Mancini,Leslie A. Brents,Shaji Kumar,Philip R. Greipp,Angela Dispenzieri,Barb Bryant,George Mulligan,Laurakay Bruhn,Michael T. Barrett,Riccardo Valdez,Jeff Trent,A. Keith Stewart,John D. Carpten,P. Leif Bergsagel +29 more
TL;DR: In this paper, an integrated analysis of high-density oligonucleotide array CGH and gene expression profiling data from 155 multiple myeloma samples identified a promiscuous array of abnormalities contributing to the dysregulation of NF-kappaB in approximately 20% of patients.
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal ArticleDOI
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
Marta Chesi,Davide F. Robbiani,Michael Sebag,Wee Joo Chng,Maurizio Affer,Rodger E. Tiedemann,Riccardo Valdez,Stephen Palmer,Stephanie S. Haas,A. Keith Stewart,Rafael Fonseca,Richard Kremer,Giorgio Cattoretti,P. Leif Bergsagel +13 more
TL;DR: More frequent MYC rearrangements, elevated levels of MYC mRNA, and MYC target genes distinguish human patients with multiple myeloma from individuals with monoclonal gammopathy, implicating a causal role for MYC in the progression of monoconsistency to multipleMyeloma.
Journal ArticleDOI
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal,Paul G. Richardson,S. Vincent Rajkumar,Jesús F. San-Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Kathryn P. Corzo,Frank Campana,Solenn Le-Guennec,Franck Dubin,Kenneth C. Anderson,Vincent Rajkumar,Simon J. Harrison,Wojt Janowski,Ian Kerridge,Andrew Spencer,Michel Delforge,Karel Fostier,Philip Vlummens,Ka Lung Wu,Richard Leblanc,Michel Pavic,Michael Sebag,Roman Hájek,Vladimir Maisnar,Ludek Pour,Henrik Gregersen,Lotfi Benbouker,Denis Caillot,Martine Escoffre-Barbe,Thierry Facon,Laurent Frenzel,Cyrille Hulin,Lionel Karlin,Brigitte Kolb,Brigitte Pegourie,Aurore Perrot,Mourad Tiab,Laure Vincent,Dietger Niederwieser,Achilles Anagnostopoulos,Sosana Delimpasi,Marie Christine Kyrtsonis,Anargyros Symeonidis,Árpád Illés,Gabor Mikala,Zsolt Nagy,Sara Bringen,Paolo Corradini,Ciceri Fabio,Roberto M. Lemoli,Anna Marina Liberati,Chiara Nozzoli,Renato Zambello,Shinsuke Iida,Takashi Ikeda,Satoshi Iyama,Morio Matsumoto,Chihiro Shimazaki,Kazutaka Sunami,Kenshi Suzuki,Michihiro Uchiyama,Youngil Koh,Ki-Hyun Kim,Jae Hoon Lee,Chang-Ki Min,Hillary Blacklock,Hugh Goodman,AJ Neylon,David Simpson,Sebastian Grosicki,Artur Jurczyszyn,Adam Walter-Croneck,Krzysztof Warzocha,Luis Araujo,Claudia Moreira,Vadim A Doronin,Larisa P. Mendeleeva,Vladimir I. Vorobyev,Andrej Vranovsky,Adrian Alegre,Mercedes Gironella,Marta Sonia Gonzalez Perez,Carmen Montes,Enrique M. Ocio,Paula Rodriguez,Mats Hardling,Birgitta Lauri,Ming Chung Wang,Su Peng Yeh,Mutlu Arat,Fatih Demirkan,Zafer Gulbas,Sevgi Kalayoglu Besisik,Ihsan Karadogan,Tulin Tuglular,Ali Ünal,Filiz Vural,Jonathan Sive,Matthew Streetly,Kwee Yong,Jason Tache +111 more
TL;DR: The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomidine and dexAMethas one in patients with relapsed and refractory multiple myeloma.
Journal ArticleDOI
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij,Michael Wang,Jonathan L. Kaufman,Sagar Lonial,Andrzej Jakubowiak,A. Keith Stewart,Vishal Kukreti,Sundar Jagannath,Kevin T. McDonagh,Melissa Alsina,Nizar J. Bahlis,Frederic J. Reu,Nashat Gabrail,Andrew R. Belch,Jeffrey Matous,Peter P. Lee,Peter Rosen,Michael Sebag,David H. Vesole,Lori Kunkel,Sandra Wear,Alvin F. Wong,Robert Z. Orlowski,David S. Siegel +23 more
TL;DR: The results of the present study support the use of carfilzomib in R/R MM patients with relapsed and/or refractory multiple myeloma.